Wedbush Boosts Earnings Estimates for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Stock analysts at Wedbush increased their Q1 2025 earnings per share estimates for shares of Fennec Pharmaceuticals in a research report issued to clients and investors on Monday, March 10th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.10) per share for the quarter, up from their prior estimate of ($0.14). Wedbush has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at $0.33 EPS, Q4 2025 earnings at $0.42 EPS and FY2026 earnings at $2.20 EPS.

Other research analysts have also issued research reports about the stock. Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Tuesday.

Fennec Pharmaceuticals Stock Up 6.2 %

Shares of FENC opened at $6.51 on Thursday. The firm has a market capitalization of $179.43 million, a PE ratio of -65.09 and a beta of 0.36. The firm has a 50-day moving average price of $6.40 and a 200 day moving average price of $5.63. Fennec Pharmaceuticals has a 52-week low of $3.96 and a 52-week high of $11.49.

Institutional Investors Weigh In On Fennec Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of FENC. Advantage Alpha Capital Partners LP purchased a new position in Fennec Pharmaceuticals in the 3rd quarter worth about $264,000. State Street Corp increased its position in shares of Fennec Pharmaceuticals by 2.2% in the third quarter. State Street Corp now owns 328,259 shares of the company’s stock worth $1,641,000 after acquiring an additional 7,053 shares in the last quarter. Barclays PLC raised its holdings in shares of Fennec Pharmaceuticals by 274.3% during the third quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after acquiring an additional 22,951 shares during the period. Franklin Resources Inc. lifted its position in shares of Fennec Pharmaceuticals by 18.7% in the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock valued at $74,000 after acquiring an additional 2,330 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Fennec Pharmaceuticals by 12.9% in the 4th quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock worth $217,000 after purchasing an additional 3,911 shares during the period. 55.51% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $6.79, for a total value of $67,900.00. Following the transaction, the director now owns 68,725 shares of the company’s stock, valued at approximately $466,642.75. This represents a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 31,186 shares of company stock valued at $203,389 over the last ninety days. Insiders own 10.98% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.